$TARA
Protara Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024096252 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.260M
YoY Change -4.91%
% of Gross Profit
Research & Development $8.070M
YoY Change 29.78%
% of Gross Profit
Depreciation & Amortization $84.00K
YoY Change 20.0%
% of Gross Profit
Operating Expenses $12.33M
YoY Change 15.23%
Operating Profit -$12.33M
YoY Change 15.23%
Interest Expense $1.111M
YoY Change 32.26%
% of Operating Profit
Other Income/Expense, Net $1.111M
YoY Change 32.26%
Pretax Income -$11.22M
YoY Change 13.78%
Income Tax
% Of Pretax Income
Net Earnings -$11.22M
YoY Change 13.78%
Net Earnings / Revenue
Basic Earnings Per Share -$0.50
Diluted Earnings Per Share -$0.50
COMMON SHARES
Basic Shares Outstanding 20.63M shares 20.63M shares
Diluted Shares Outstanding 22.33M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $81.50M
YoY Change 10.08%
Cash & Equivalents $51.76M
Short-Term Investments $29.74M
Other Short-Term Assets $3.000K
YoY Change 50.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $85.08M
YoY Change 9.34%
LONG-TERM ASSETS
Property, Plant & Equipment $1.109M
YoY Change -20.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K
YoY Change -98.88%
Total Long-Term Assets $9.008M
YoY Change -15.45%
TOTAL ASSETS
Total Short-Term Assets $85.08M
Total Long-Term Assets $9.008M
Total Assets $94.09M
YoY Change 6.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.295M
YoY Change -8.35%
Accrued Expenses $5.268M
YoY Change 59.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.642M
YoY Change 27.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $3.657M
YoY Change -22.19%
Total Long-Term Liabilities $3.657M
YoY Change -22.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.642M
Total Long-Term Liabilities $3.657M
Total Liabilities $12.30M
YoY Change 6.85%
SHAREHOLDERS EQUITY
Retained Earnings -$232.2M
YoY Change 22.11%
Common Stock $21.00K
YoY Change 90.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $81.79M
YoY Change
Total Liabilities & Shareholders Equity $94.09M
YoY Change 6.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$11.22M
YoY Change 13.78%
Depreciation, Depletion And Amortization $84.00K
YoY Change 20.0%
Cash From Operating Activities -$8.434M
YoY Change 28.57%
INVESTING ACTIVITIES
Capital Expenditures $8.000K
YoY Change -80.0%
Acquisitions
YoY Change
Other Investing Activities -$29.38M
YoY Change -558.38%
Cash From Investing Activities -$29.39M
YoY Change -560.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -8.434M
Cash From Investing Activities -29.39M
Cash From Financing Activities 0.000
Net Change In Cash -37.82M
YoY Change 17911.43%
FREE CASH FLOW
Cash From Operating Activities -$8.434M
Capital Expenditures $8.000K
Free Cash Flow -$8.442M
YoY Change 27.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
745000 usd
CY2023Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
39031000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
23495000 usd
CY2023Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
745000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
931000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1447000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3221000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4640000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11219000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9860000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31827000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30199000 usd
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22329772 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22329772 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11347887 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11347887 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18342566 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18342566 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11320027 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11320027 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.5
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.5
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.67
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1700000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23256489 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11453221 shares
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
tara Proceeds From Issuance Of Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
CY2023Q4 tara Prepaid Retention Bonuses
PrepaidRetentionBonuses
usd
CY2024Q3 tara Accrued Interest On Marketable Debt Securities
AccruedInterestOnMarketableDebtSecurities
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001359931
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36694
dei Entity Registrant Name
EntityRegistrantName
Protara Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4580525
dei Entity Address Address Line1
EntityAddressAddressLine1
345 Park Avenue South
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10010
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
844-0337
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TARA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20629772 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51757000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39586000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29742000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
25994000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3583000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3125000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
85082000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
68705000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
745000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
745000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1109000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1296000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4514000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5264000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
2640000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
2944000 usd
CY2024Q3 us-gaap Assets
Assets
94090000 usd
CY2023Q4 us-gaap Assets
Assets
78954000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2295000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2434000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5268000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2732000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1079000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
983000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8642000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6149000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3657000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4484000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
12299000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
10633000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20629772 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20629772 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11364903 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11364903 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
21000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
313952000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
268725000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-232211000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-200384000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-31000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
81791000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
68321000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94090000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78954000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8070000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6218000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22205000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18608000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4260000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4482000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12637000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13964000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12330000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10700000 usd
us-gaap Operating Expenses
OperatingExpenses
34842000 usd
us-gaap Operating Expenses
OperatingExpenses
32572000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12330000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10700000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-34842000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32572000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1111000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
840000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3015000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2373000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1111000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
840000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3015000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2373000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11219000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9860000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31827000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30199000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.5
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.5
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.67
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22329772 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22329772 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11347887 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11347887 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18342566 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18342566 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11320027 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11320027 shares
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
29000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
171000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
60000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
523000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
29000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
171000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
60000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
523000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11190000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9689000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31767000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29676000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
102083000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-64000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
314000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1261000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
219000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9045000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
94768000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
326000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1292000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
133000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11294000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
85225000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-27000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
275000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1172000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
171000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9860000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
76956000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
68321000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-76000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
151000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1075000 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11095000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
58406000 usd
CY2024Q2 tara Offering Costs
OfferingCosts
3034000 usd
CY2024Q2 tara Issuance Of Common Stock Warrants Prefunded Warrants In Private Placement Net Of Offering Costs
IssuanceOfCommonStockWarrantsPrefundedWarrantsInPrivatePlacementNetOfOfferingCosts
41964000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-7000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
111000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
953000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-9513000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
92050000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
109000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
822000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
29000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-11219000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
81791000 usd
us-gaap Net Income Loss
NetIncomeLoss
-31827000 usd
us-gaap Net Income Loss
NetIncomeLoss
-30199000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3221000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4640000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
750000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
711000 usd
us-gaap Depreciation
Depreciation
250000 usd
us-gaap Depreciation
Depreciation
234000 usd
tara Amortization Of Discounts And Premiums Investments
AmortizationOfDiscountsAndPremiumsInvestments
-406000 usd
tara Amortization Of Discounts And Premiums Investments
AmortizationOfDiscountsAndPremiumsInvestments
-331000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
458000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1919000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-304000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2297000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-139000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
918000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2536000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
68000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-731000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-682000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26500000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28857000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
29382000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
12186000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26100000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50820000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3345000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38589000 usd
tara Offering Costs
OfferingCosts
3034000 usd
tara Proceeds From Issuance Of Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts
41964000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
135000 usd
tara Payments Of Taxes Related To Net Share Settlement Of Restricted Stock Units
PaymentsOfTaxesRelatedToNetShareSettlementOfRestrictedStockUnits
83000 usd
tara Payments Of Taxes Related To Net Share Settlement Of Restricted Stock Units
PaymentsOfTaxesRelatedToNetShareSettlementOfRestrictedStockUnits
91000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42016000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-91000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12171000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
9641000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40331000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24872000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52502000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34513000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
51757000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
33768000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
745000 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
745000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52502000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34513000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. Organization and Nature of the Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Overview</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Protara Therapeutics, Inc., and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer, or NMIBC, and lymphatic malformations, or LMs. Additionally, the Company’s portfolio includes Intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy in development for patients receiving parenteral support, or PS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Liquidity and Capital Resources</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Significant items subject to such estimates include but are not limited to research and development accruals as well as contingencies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments, which potentially subject the Company to concentrations of credit risk, consists principally of cash and cash equivalents, restricted cash and investments in marketable debt securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company currently invests its excess cash primarily in money market funds and high quality investment grade marketable debt securities of governments and corporations. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</p>
CY2024Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
41266000 usd
CY2024Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
9989000 usd
CY2024Q3 tara Us Treasury Securities At Fair Value
USTreasurySecuritiesAtFairValue
29742000 usd
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
81742000 usd
CY2023Q4 tara Agency Bonds
AgencyBonds
2499000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
65770000 usd
CY2023Q4 tara Estimated Fair Value
EstimatedFairValue
25994000 usd
CY2023Q4 tara Unrealized Losses
UnrealizedLosses
-31000 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
659000 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
710000 usd
us-gaap Interest Income Other
InterestIncomeOther
2468000 usd
us-gaap Interest Income Other
InterestIncomeOther
2025000 usd
CY2024Q3 us-gaap Dividend Income Operating
DividendIncomeOperating
8000 usd
CY2023Q3 us-gaap Dividend Income Operating
DividendIncomeOperating
2000 usd
us-gaap Dividend Income Operating
DividendIncomeOperating
28000 usd
us-gaap Dividend Income Operating
DividendIncomeOperating
6000 usd
CY2024Q3 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
444000 usd
CY2023Q3 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
128000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
519000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
342000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1111000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
840000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3015000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2373000 usd
CY2024Q3 tara Prepaid Research And Development
PrepaidResearchAndDevelopment
2640000 usd
CY2023Q4 tara Prepaid Research And Development
PrepaidResearchAndDevelopment
1957000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
360000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
659000 usd
CY2024Q3 tara Prepaid Retention Bonuses
PrepaidRetentionBonuses
140000 usd
CY2024Q3 tara Prepaid Software
PrepaidSoftware
99000 usd
CY2023Q4 tara Prepaid Software
PrepaidSoftware
67000 usd
CY2023Q4 tara Accrued Interest On Marketable Debt Securities
AccruedInterestOnMarketableDebtSecurities
242000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
341000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
163000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
37000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3583000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3125000 usd
CY2024Q3 tara Prepaid Research And Development Noncurrent
PrepaidResearchAndDevelopmentNoncurrent
2539000 usd
CY2023Q4 tara Prepaid Research And Development Noncurrent
PrepaidResearchAndDevelopmentNoncurrent
2661000 usd
CY2024Q3 tara Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
68000 usd
CY2023Q4 tara Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
272000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11000 usd
CY2024Q3 us-gaap Other Assets
OtherAssets
2640000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
2944000 usd
CY2024Q3 tara Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3385000 usd
CY2023Q4 tara Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
440000 usd
CY2024Q3 tara Accrued Employee Related Current
AccruedEmployeeRelatedCurrent
1515000 usd
CY2023Q4 tara Accrued Employee Related Current
AccruedEmployeeRelatedCurrent
2112000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
368000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
180000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5268000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2732000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
995000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
995000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
338000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
341000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1014000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1024000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
338000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
341000 usd
us-gaap Lease Cost
LeaseCost
1014000 usd
us-gaap Lease Cost
LeaseCost
1024000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
26000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
72000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07 pure
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P46M
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
332000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1395000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1429000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1429000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
718000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
87000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5390000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
654000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4736000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20629772 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20629772 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11364903 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11364903 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
931000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1447000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3221000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4640000 usd

Files In Submission

Name View Source Status
0001213900-24-096252-index-headers.html Edgar Link pending
0001213900-24-096252-index.html Edgar Link pending
0001213900-24-096252.txt Edgar Link pending
0001213900-24-096252-xbrl.zip Edgar Link pending
ea0219261-10q_protara.htm Edgar Link pending
ea021926101ex31-1_protara.htm Edgar Link pending
ea021926101ex31-2_protara.htm Edgar Link pending
ea021926101ex32-1_protara.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ea0219261-10q_protara_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tara-20240930.xsd Edgar Link pending
tara-20240930_def.xml Edgar Link unprocessable
tara-20240930_lab.xml Edgar Link unprocessable
tara-20240930_pre.xml Edgar Link unprocessable
tara-20240930_cal.xml Edgar Link unprocessable